The Biosimilar Shift: Trending Infliximab Biosimilar Utilization and Associated Cost Savings for Commercial Insurance
Utilization of infliximab biosimilars steadily increased in the first 5 years after market entry. The competition created by biosimilars has contributed to significant health care savings and a decrease in the total cost of both the infliximab originator drug and its biosimilars.
Authors
- Jennifer L. Dotson (ORCID: https://orcid.org/0000-0001-6193-3179)
- Mahmoud Abdel‐Rasoul (ORCID: https://orcid.org/0000-0003-0653-0718)
- Hilary K. Michel (ORCID: https://orcid.org/0000-0002-1742-936X)
- Ross Maltz (ORCID: https://orcid.org/0000-0001-7850-7555)
- Samantha Paglinco
- Brendan Boyle (ORCID: https://orcid.org/0000-0002-6679-1584)
- Morgane C. Mouslim (ORCID: https://orcid.org/0000-0002-6999-7588)
- Megan McNicol
Institutions
- St. Christopher's Hospital for Children (US)
Publication Details
- Journal
- The American Journal of Managed Care
- Published
- 2025-10-14
- DOI
- https://doi.org/10.37765/ajmc.2025.89811
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00